Research | Page 16 of 22

Enzyme Linked to Insulin Resistance May Lead to New Treatment for Type 2 Diabetes

Researchers at Joslin Diabetes Center have identified an enzyme called PKC-delta as an important molecular modifier for development of insulin resistance, diabetes and fatty liver in mice. They also have found evidence suggesting a similar role for the enzyme in humans...

Team Type 1 Launches First Clinical Study in Athletes with Type 1 Diabetes

Global sports organization Team Type 1, the official parent company of the Team Type 1- sanofi aventis professional men’s cycling team, announced the launch a clinical study at the Amgen Tour of California. The pioneering study conducted by the Team Type 1 Diabetes Sports Research Institute, will assess blood glucose levels of elite cyclists...

Researchers Discover Mechanism That Converts Certain Cells into Insulin Producing Beta Cells

Researchers from UCLA's Larry L. Hillblom Islet Research Center have discovered the underlying mechanism that could convert other cell types into pancreatic beta cells. It had long been assumed that the identity of cells was "locked" into place and that they could not be switched into other cell types...

Shed a Tear for Diabetes: The Development of a Tear Glucose Sensor

We touch the eye, but only the white part, the conjunctiva, for around 5 seconds...

Sanofi-aventis and Columbia University to Collaborate on Diabetes Research

Sanofi-aventis and Columbia University Medical Center announced a three-year research collaboration for the development of innovative diabetes medicines. This research collaboration, with the laboratory of Dr. Gerard Karsenty, will investigate the role of the osteoblast-secreted peptide, osteocalcin, in diabetes management...

XOMA Type 2 Diabetes Drug Fails to Meet End Point in Phase 2 Trials

XOMA Ltd. announced that its phase 2b trial of XOMA 052 in type 2 diabetes patients did not achieve the primary endpoint of reduction of HbA1c after six monthly treatments with XOMA 052 compared to placebo. Biological activity of XOMA 052 supporting its potential...

NYU and Pluristem Partner in Study of Cell-Based Treatment for Diabetic Foot Ulcers

Pluristem Therapeutics, Inc., an Israeli based company developing placenta-based cell therapies, and New York University (NYU) Medical Center today announced the formation of a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the treatment of diabetic foot ulcers...

GSK Type 1 Diabetes Drug, Otelixizumab, Fails in Phase 3 Study

GlaxoSmithKline and Tolerx, Inc's Investigatinal immunotherapy, Otelixizumab, for type 1 diabetes failed to meet primary end point in the Phase 3 DEFEND-1 study. Otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide...

Brain Insulin May be a Cause of Type 2 Diabetes and Obesity

Researchers from Mount Sinai School of Medicine have discovered a novel function of brain insulin, indicating that impaired brain insulin action may be the cause of the unrestrained lipolysis that initiates and worsens type 2 diabetes in humans...

Robotic Drug May Prove a Good Treatment for Diabetic Foot Ulcers

Harvard University and Hebrew University scientists have developed a low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns. Several proteins, called growth factors, have been found to speed up the healing process, however purifying these growth factor proteins is very expensive, and they do not last long on the injured site....